TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

H M Earl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.